candesartan has been researched along with Reperfusion Injury in 17 studies
candesartan: a nonpeptide angiotensin II receptor antagonist
candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.
Reperfusion Injury: Adverse functional, metabolic, or structural changes in tissues that result from the restoration of blood flow to the tissue (REPERFUSION) following ISCHEMIA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Pretreatment with candesartan, spironolactone, or candesartan and spironolactone significantly inhibited retinal ischemic injury." | 5.38 | Activation of the aldosterone/mineralocorticoid receptor system and protective effects of mineralocorticoid receptor antagonism in retinal ischemia-reperfusion injury. ( Fujita, T; Hirooka, K; Itano, T; Lei, B; Liu, Y; Nakamura, T; Nishiyama, A; Shiraga, F; Zhang, J, 2012) |
| " We hypothesized that aging results in enhanced early reperfusion injury and left ventricular remodeling after reperfused ST-segment-elevation myocardial infarction and that early therapy initiated at the time of reperfusion with an angiotensin II type 1 receptor blocker such as candesartan attenuates age-related increases in reperfusion injury and remodeling." | 3.76 | Aging-related early changes in markers of ventricular and matrix remodeling after reperfused ST-segment elevation myocardial infarction in the canine model: effect of early therapy with an angiotensin II type 1 receptor blocker. ( Idikio, H; Jelani, A; Jugdutt, BI; Jugdutt, CE; Menon, V; Palaniyappan, A; Uweira, RE, 2010) |
| " In this study, we investigated the effect of postischemic treatment using the angiotensin II type 1 receptor blocker, candesartan, on brain damage in focal cerebral ischemia." | 3.75 | Postischemic administration of angiotensin II type 1 receptor blocker reduces cerebral infarction size in hypertensive rats. ( Kitagawa, K; Okazaki, S; Omura-Matsuoka, E; Oyama, N; Sakoda, S; Sasaki, T; Sugiyama, Y; Terasaki, Y; Yagita, Y, 2009) |
| " Recent studies demonstrated an angiotensin II type 1 (AT1)-receptor antagonist reduced myocardial ischemia-reperfusion injury." | 3.71 | Influence of angiotensin II type 1-receptor antagonist CV11974 on infarct size and adjacent regional function after ischemia-reperfusion in dogs. ( Imuro, Y; Iwasaka, T; Izuoka, T; Kitashiro, S; Mimura, J; Miyoshi, H; Saito, D; Takayama, Y; Tokioka, M; Yamamoto, S, 2002) |
| "It is not yet clear if cardiac angiotensin II is involved in the pathophysiology of myocardial ischemia/ reperfusion injury." | 3.70 | The angiotensin II AT1-receptor antagonist candesartan improves functional recovery and reduces the no-reflow area in reperfused ischemic rat hearts. ( Rydén, L; Shimizu, M; Sjöquist, PO; Wang, QD, 1999) |
| "Pretreatment with candesartan, spironolactone, or candesartan and spironolactone significantly inhibited retinal ischemic injury." | 1.38 | Activation of the aldosterone/mineralocorticoid receptor system and protective effects of mineralocorticoid receptor antagonism in retinal ischemia-reperfusion injury. ( Fujita, T; Hirooka, K; Itano, T; Lei, B; Liu, Y; Nakamura, T; Nishiyama, A; Shiraga, F; Zhang, J, 2012) |
| "Pretreatment with captopril or candesartan significantly inhibited the ischemic injury of the inner retina." | 1.36 | Neuroprotection against retinal ischemia-reperfusion injury by blocking the angiotensin II type 1 receptor. ( Fukuda, K; Hirooka, K; Itano, T; Mizote, M; Nakamura, T; Shiraga, F, 2010) |
| "Candesartan treatment normalised the lower part of the autoregulatory curve in SHR, and markedly decreased cerebral ischaemia as a consequence of middle cerebral artery occlusion with reperfusion." | 1.31 | Pre-treatment with candesartan protects from cerebral ischaemia. ( Ito, T; Nishimura, Y; Saavedra, J, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (11.76) | 18.2507 |
| 2000's | 8 (47.06) | 29.6817 |
| 2010's | 7 (41.18) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Panahpour, H | 1 |
| Nekooeian, AA | 1 |
| Dehghani, GA | 1 |
| Omura-Matsuoka, E | 1 |
| Yagita, Y | 1 |
| Sasaki, T | 1 |
| Terasaki, Y | 1 |
| Oyama, N | 1 |
| Sugiyama, Y | 1 |
| Okazaki, S | 1 |
| Sakoda, S | 1 |
| Kitagawa, K | 1 |
| Gemici, B | 1 |
| Tan, R | 1 |
| Ongüt, G | 1 |
| Izgüt-Uysal, VN | 1 |
| Fukuda, K | 1 |
| Hirooka, K | 3 |
| Mizote, M | 1 |
| Nakamura, T | 3 |
| Itano, T | 3 |
| Shiraga, F | 3 |
| Jugdutt, BI | 1 |
| Jelani, A | 1 |
| Palaniyappan, A | 1 |
| Idikio, H | 1 |
| Uweira, RE | 1 |
| Menon, V | 1 |
| Jugdutt, CE | 1 |
| Gaur, V | 1 |
| Kumar, A | 1 |
| Liu, Y | 1 |
| Nishiyama, A | 2 |
| Lei, B | 1 |
| Fujita, T | 2 |
| Zhang, J | 1 |
| Nagai, Y | 1 |
| Miyoshi, H | 1 |
| Takayama, Y | 1 |
| Kitashiro, S | 1 |
| Izuoka, T | 1 |
| Saito, D | 1 |
| Imuro, Y | 1 |
| Mimura, J | 1 |
| Yamamoto, S | 1 |
| Tokioka, M | 1 |
| Iwasaka, T | 1 |
| Takagi, T | 1 |
| Yoshida, N | 1 |
| Isozaki, Y | 1 |
| Shimozawa, M | 1 |
| Katada, K | 1 |
| Manabe, H | 1 |
| Hanada, O | 1 |
| Kokura, S | 1 |
| Ichikawa, H | 1 |
| Naito, Y | 1 |
| Okanoue, T | 1 |
| Yoshikawa, T | 1 |
| Engelhorn, T | 1 |
| Doerfler, A | 1 |
| Heusch, G | 1 |
| Schulz, R | 1 |
| Brdon, J | 1 |
| Kaiser, S | 1 |
| Hagemann, F | 1 |
| Zhao, Y | 1 |
| Culman, J | 1 |
| Gohlke, P | 1 |
| Nakagiri, A | 1 |
| Sunamoto, M | 1 |
| Murakami, M | 1 |
| Shimizu, M | 2 |
| Wang, QD | 2 |
| Sjöquist, PO | 2 |
| Rydén, L | 2 |
| Masuko, H | 1 |
| Jin, MB | 1 |
| Horiuchi, H | 1 |
| Suzuki, T | 1 |
| Taniguchi, M | 1 |
| Shimamura, T | 1 |
| Fukai, M | 1 |
| Magata, S | 1 |
| Ogata, K | 1 |
| Ishikawa, H | 1 |
| Fujita, M | 1 |
| Nagashima, K | 1 |
| Furukawa, H | 1 |
| Todo, S | 1 |
| Ito, T | 1 |
| Nishimura, Y | 1 |
| Saavedra, J | 1 |
17 other studies available for candesartan and Reperfusion Injury
| Article | Year |
|---|---|
Candesartan attenuates ischemic brain edema and protects the blood-brain barrier integrity from ischemia/reperfusion injury in rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Blood-Brain Ba | 2014 |
Postischemic administration of angiotensin II type 1 receptor blocker reduces cerebral infarction size in hypertensive rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Blood Pressure | 2009 |
Expressions of inducible nitric oxide synthase and cyclooxygenase-2 in gastric ischemia-reperfusion: role of angiotensin II.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin II Type 2 Receptor Blockers; An | 2010 |
Neuroprotection against retinal ischemia-reperfusion injury by blocking the angiotensin II type 1 receptor.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin II Type 2 Receptor Blockers; Angiotensin-Conver | 2010 |
Aging-related early changes in markers of ventricular and matrix remodeling after reperfused ST-segment elevation myocardial infarction in the canine model: effect of early therapy with an angiotensin II type 1 receptor blocker.
Topics: Aging; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; A | 2010 |
Neuroprotective potentials of candesartan, atorvastatin and their combination against stroke induced motor dysfunction.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Atorvastatin; Behavior, Animal; Benzimidazoles; Bi | 2011 |
Activation of the aldosterone/mineralocorticoid receptor system and protective effects of mineralocorticoid receptor antagonism in retinal ischemia-reperfusion injury.
Topics: Aldosterone; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; C | 2012 |
Neuroprotective effects of angiotensin II type 1 receptor (AT1-R) blocker via modulating AT1-R signaling and decreased extracellular glutamate levels.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Cell Survival; | 2012 |
Influence of angiotensin II type 1-receptor antagonist CV11974 on infarct size and adjacent regional function after ischemia-reperfusion in dogs.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Biphenyl Compounds; Dogs; | 2002 |
CV-11974, angiotensin II type I receptor antagonist, protects against ischemia-reperfusion injury of the small intestine in rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Cell Adhesion; | 2006 |
Reduction of cerebral infarct size by the AT1-receptor blocker candesartan, the HMG-CoA reductase inhibitor rosuvastatin and their combination. An experimental study in rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Brain; Cerebra | 2006 |
Comparison between early and delayed systemic treatment with candesartan of rats after ischaemic stroke.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Blood Pressure | 2007 |
Angiotensin AT1 receptor blockers suppress ischemia/reperfusion-induced gastric injury in rats.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds | 2007 |
The angiotensin II AT1-receptor antagonist candesartan improves functional recovery and reduces the no-reflow area in reperfused ischemic rat hearts.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; | 1999 |
The angiotensin II AT1 receptor antagonist candesartan at antihypertensive plasma concentrations reduces damage induced by ischemia-reperfusion.
Topics: Anesthesia; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Ant | 1999 |
Protective effect of agiotensin II type I receptor antagonist, CV-11974, on ischemia and reperfusion injury of the liver.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Aspartate Aminotransferases; Benzimidazol | 2001 |
Pre-treatment with candesartan protects from cerebral ischaemia.
Topics: Angiotensin Receptor Antagonists; Animals; Arterial Occlusive Diseases; Benzimidazoles; Biphenyl Com | 2001 |